Cited by 297Treatment of Major DepressionSuicide and Self-Harm StudiesElectroconvulsive Therapy Studies

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial

Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M. +9 more·2015·Psychological Medicine

Abstract

Background.: Suicide is a devastating public health problem and very few biological treatments have been found to be effective for quickly reducing the intensity of suicidal ideation (SI). We have previously shown that a single dose of ketamine, a glutamate N -methyl- d -aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression. Method.: We conducted a randomized, controlled trial of ketamine in patients with mood and anxiety spectrum disorders who presented with clinically significant SI ( n = 24). Patients received a single infusion of ketamine or midazolam (as an active placebo) in addition to standard of care. SI measured using the Beck Scale for Suicidal Ideation (BSI) 24 h post-treatment represented the primary outcome. Secondary outcomes included the Montgomery–Asberg Depression Rating Scale – Suicidal Ideation (MADRS-SI) score at 24 h and additional measures beyond the 24-h time-point. Results.: The intervention was well tolerated and no dropouts occurred during the primary 7-day assessment period. BSI score was not different between the treatment groups at 24 h ( p = 0.32); however, a significant difference emerged at 48 h ( p = 0.047). MADRS-SI score was lower in the ketamine group compared to midazolam group at 24 h ( p = 0.05). The treatment effect was no longer significant at the end of the 7-day assessment period. Conclusions.: The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior. Larger, well-powered studies are warranted.

Integrity signals

Registry

Crossref · 10.1017/s0033291715001506

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Altered expression of NMDA, AMPA, and kainite glutamate receptors is linked to suicidal behavior and may play a role in the rapid-onset antidepressant and antisuicidal effects of ketamine.

    “Altered expression of glutamate receptor N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainite glutamate receptors is linked to suicidal behavior (129) and may play a role in the rapid-onset antidepressant and antisuicidal effects of ketamine (130-135).”

    From A brain-centric model of suicidal behavior (2020) · cites this paper as [133]

  • The anti-suicidal ideation effect of ketamine is only partly explained by its antidepressant action, and effects on memory and cognition may also play a role.

    “The anti–suicidal ideation effect of ketamine is only partly explained by its antidepressant action, and effects on memory and cognition may also play a role (131-133).”

    From A brain-centric model of suicidal behavior (2020) · cites this paper as [133]

  • Intravenous ketamine rapidly reduces depressive symptoms and suicidal ideation in hours instead of weeks.

    “Intravenous ketamine is a rapidly acting treatment that robustly reduces depressive symptoms and suicidal ideation in hours instead of weeks (130-133).”

    From A brain-centric model of suicidal behavior (2020) · cites this paper as [133]

  • Ketamine's emergent use on suicidal ideation has short-lived effects for some suicidal patients.

    “the emergent use of ketamine on suicidal ideation for a few days [14] has short-lived effects for some suicidal patients.”

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., Price, R. B., Perez, A. M., Brallier, J. W., Rodriguez, G. J., Goodman, W. K., Iosifescu, D. V., & Charney, D. S.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • Stony Brook University (US)
  • University of California, Los Angeles (US)
  • Drexel University (US)
  • University of Pittsburgh (US)
Corresponding author
Murrough, J. W.
Venue
Psychological Medicine
Published
2015-08-12
Volume
45
Issue
16
Pages
3571-3580
ISSN
  • 0033-2917 (ISSN-L)
  • 1469-8978
OpenAlex
W1885564923
Cited by
297
References
52
Citations by year
2026: 11 · 2025: 17 · 2024: 21 · 2023: 31 · 2022: 33 · 2021: 38 · 2020: 43 · 2019: 30 · 2018: 29 · 2017: 20 · 2016: 19 · 2015: 5
FWCI
17.56
Type
journal article
Language
en
Open access
closed
Locations
  • Psychological Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Brain and Behavior Research Foundation
  • Brain Research Foundation
  • BrainsWay
  • National Institutes of Health
  • National Institute of Mental Health (K23MH104465)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
ketamine, suicidal ideation, NMDA receptor antagonists, rapid-acting antidepressants, treatment-resistant depression, suicide risk, safety and tolerability
MeSH terms
Adult, Bipolar Disorder, Depression, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Stress Disorders, Post-Traumatic, Treatment Outcome, Excitatory Amino Acid Antagonists, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review